The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study

This is the authors' abstract. We don't add key points for this paper.

Immune checkpoint inhibitors (ICIs) induce antitumor effects by enhancing the host immune system to eliminate cancer cells.1 Because of nonspecific immune activation, ICIs cause immune-related adverse events (irAEs), including cutaneous irAEs (cirAEs), which affect approximately 40% of patients.2 CirAEs are associated with increased progression-free survival, but can negatively impact patient quality of life or necessitate ICI discontinuation.3 CirAEs typically occur within 4 to 8 weeks of ICI initiation and can occur at any point during or after treatment.